Haoyuan Chemexpress 皓元医药
25 significant filings since 31 May 2026: 1 on shares frozen, 12 on share issue and 7 on dividend, and 3 other kinds. The latest, on 14 Sep 2026: 上海皓元医药股份有限公司2026年半年度权益分派实施公告.
自 31 May 2026 起有 25 份重大公告：shares frozen 1 份、share issue 12 份、dividend 7 份，另有 3 类。最新一份（14 Sep 2026）：上海皓元医药股份有限公司2026年半年度权益分派实施公告。
Price History 价格走势
5 sessions 个交易日, 21 Sep to 28 Sep 2026 · Live one-minute prices · High 最高 ¥110.85 · Low 最低 ¥97.80 · −3.64% on the previous close of ¥103.54The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 6 Mar 2022 | 华金证券 | 李蕙,魏赟 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 余汝意 | Buy 买入 | 28 Aug 2026 | 1 | — |
| 长城国瑞证券 | 胡晨曦,魏钰琪 | Outperform 增持 | 18 May 2026 | 1 | — |
| 东吴证券 | 朱国广,刘若彤 | Buy 买入 | 6 May 2026 | 1 | — |
| 太平洋 | 周豫,张崴 | Buy 买入 | 1 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 4 reports. 每行为该券商近十二个月的最新研报；4 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。